|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
2012
specific CFTR mutations
|
|
gptkbp:category
|
orphan drug
|
|
gptkbp:combinationTherapy
|
gptkb:elexacaftor/tezacaftor/ivacaftor
gptkb:ivacaftor/lumacaftor
gptkb:ivacaftor/tezacaftor
|
|
gptkbp:contraindication
|
severe liver impairment
|
|
gptkbp:discoveredBy
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:effect
|
improve quality of life
improve lung function
reduce pulmonary exacerbations
|
|
gptkbp:includes
|
gptkb:elexacaftor
gptkb:ivacaftor
gptkb:lumacaftor
gptkb:tezacaftor
|
|
gptkbp:marketedAs
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
modulate CFTR channel function
|
|
gptkbp:metabolism
|
gptkb:CYP3A
|
|
gptkbp:notEffectiveAgainst
|
all CFTR mutations
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
headache
upper respiratory tract infection
increased liver enzymes
|
|
gptkbp:target
|
gptkb:CFTR_protein
|
|
gptkbp:usedFor
|
cystic fibrosis
|
|
gptkbp:bfsParent
|
gptkb:Cystic_fibrosis
gptkb:Cystic_Fibrosis
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CFTR modulators
|